Huapont Life Sciences released its 2026 interim report, with net profit attributable to the parent company of 319 million yuan, down 17.79% from the same period last year. Total operating revenue was 5.91 billion yuan, down 0.59% year on year. Net cash inflow from operating activities was 651 million yuan, up 21.37% year on year, marking a third consecutive year of growth. The company's latest debt-to-asset ratio was 42.01%, down 4.15 percentage points from a year earlier. The latest gross margin was 37.83%, up 1.55 percentage points year on year. The latest return on equity was 3.16%, down 0.82 percentage points from a year earlier. Diluted earnings per share were 0.16 yuan, down 17.78% year on year.
Huapont Life Sciences Co LtdNet profit down 17.79% year on year in interim report.
